Citigroup’s Akero Therapeutics AKRO Stock Holding History

Citigroup’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-27,000	Closed	-$1.44M	–	6061
2025 Q2	$1.44M	Sell	27,000 -15,000	-36%	-$682K	﹤0.01%	2934
2025 Q1	$1.7M	Buy	+42,000	New	+$1.78M	﹤0.01%	2849
2024 Q1	–	Sell	-5,000	Closed	-$117K	–	5618
2023 Q4	$117K	Hold	5,000	–	–	﹤0.01%	4137
2023 Q3	$253K	Sell	5,000 -57,500	-92%	-$2.68M	﹤0.01%	3539
2023 Q2	$2.92M	Buy	+62,500	New	+$2.86M	﹤0.01%	1879

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Citigroup's AKRO Position: Q4 2025 in Review

Citigroup sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 17,118 shares — an estimated $813K sold.

Citigroup first reported a position in AKRO in Q3 2019 and held it in 25 quarters. The position peaked at $9.48M in Q1 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

Citigroup reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
Citigroup sold 17,118 Akero Therapeutics shares in Q4 2025, an estimated $813K.
Citigroup first reported a position in Akero Therapeutics in Q3 2019 and held it in 25 quarters.
Citigroup's Akero Therapeutics position peaked at $9.48M in Q1 2025.
2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Citigroup's 13F filing for Q4 2025, filed 13 Feb 2026.